HK1096032A1 - Solid dispersions comprising tacrolimus - Google Patents

Solid dispersions comprising tacrolimus

Info

Publication number
HK1096032A1
HK1096032A1 HK07103423.4A HK07103423A HK1096032A1 HK 1096032 A1 HK1096032 A1 HK 1096032A1 HK 07103423 A HK07103423 A HK 07103423A HK 1096032 A1 HK1096032 A1 HK 1096032A1
Authority
HK
Hong Kong
Prior art keywords
tacrolimus
solid dispersions
solid
hydrophilic
dispersed
Prior art date
Application number
HK07103423.4A
Other languages
English (en)
Inventor
Per Holm
Tomas Norling
Original Assignee
Lifecycle Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma As filed Critical Lifecycle Pharma As
Publication of HK1096032A1 publication Critical patent/HK1096032A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK07103423.4A 2003-08-29 2007-03-30 Solid dispersions comprising tacrolimus HK1096032A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301232 2003-08-29
DKPA200301837 2003-12-11
US52979303P 2003-12-15 2003-12-15
DKPA200400079 2004-01-21
DKPA200400463 2004-03-23
DKPA200400467 2004-03-23
PCT/DK2004/000574 WO2005020994A1 (en) 2003-08-29 2004-08-30 Solid dispersions comprising tacrolimus

Publications (1)

Publication Number Publication Date
HK1096032A1 true HK1096032A1 (en) 2007-05-25

Family

ID=34280179

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103423.4A HK1096032A1 (en) 2003-08-29 2007-03-30 Solid dispersions comprising tacrolimus

Country Status (12)

Country Link
US (15) US7994214B2 (xx)
EP (2) EP1663217B1 (xx)
JP (2) JP4996249B2 (xx)
AT (1) ATE473003T1 (xx)
AU (2) AU2004267910B2 (xx)
BR (2) BRPI0413927B8 (xx)
CA (2) CA2537044C (xx)
DE (1) DE602004028023D1 (xx)
HK (1) HK1096032A1 (xx)
NO (2) NO337869B1 (xx)
PL (2) PL1663217T3 (xx)
WO (2) WO2005020994A1 (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000370A (es) * 2003-07-09 2006-03-28 Chong Kun Dang Pharm Corp Dispersion solida de tacrolimus.
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
EA200701998A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции для инъекций наночастиц иммунодепрессивных соединений
EP1896075A2 (en) * 2005-06-22 2008-03-12 LifeCycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
EP1942887A1 (en) * 2005-10-07 2008-07-16 LifeCycle Pharma A/S Tacrolimus combination products
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
US20080031949A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. High dose orally dissolvable/disintegrable lyophilized dosage form
WO2008041553A1 (fr) * 2006-09-26 2008-04-10 Astellas Pharma Inc. Préparation à libération entretenue de tacrolimus
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
WO2009022354A2 (en) * 2007-03-29 2009-02-19 Panacea Biotec Limited. Modified dosage forms of tacrolimus
JP2010523554A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド タクロリムスの医薬組成物
ITMI20070720A1 (it) * 2007-04-06 2008-10-07 Monteresearch Srl Composizioni orali contenenti tacrolimus in forma amorfa
MX2009011493A (es) * 2007-04-25 2009-11-09 Teva Pharma Complejo de excipiente farmaceutico.
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US20220193046A1 (en) * 2007-05-30 2022-06-23 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
CA2689978A1 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TW200932240A (en) * 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2009080030A1 (en) * 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US20230101012A1 (en) * 2008-05-30 2023-03-30 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
CA2729948C (en) * 2008-07-08 2021-11-23 Lifecycle Pharma A/S Tacrolimus for improved treatment of transplant patients
AU2009302818A1 (en) * 2008-10-10 2010-04-15 Alvine Pharmaceuticals, Inc. Dosage forms that facilitate rapid activation of zymogen
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
CA2762179A1 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
IN2012DN00781A (xx) 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
EA027869B1 (ru) * 2010-02-17 2017-09-29 Велоксис Фармасьютикалз А/С Стабилизированная композиция такролимуса
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA2819130A1 (en) * 2010-12-07 2012-06-14 The Johns Hopkins University Compositions and methods for mobilizing stem cells
KR20130028824A (ko) * 2011-09-09 2013-03-20 주식회사 삼양바이오팜 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법
EP2836200B1 (en) * 2012-04-08 2020-07-15 Urogen Pharma Ltd. Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
US9078925B2 (en) * 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CA2878689A1 (en) * 2012-07-12 2014-01-16 Abbvie Inc. Crystalline forms of an hcv inhibitor
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
ES2927803T3 (es) 2013-04-29 2022-11-11 Medregen Llc Curación de heridas mediante la movilización de células madre autólogas
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ES2858517T3 (es) 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Composiciones que comprenden ciclosporina
MX2018001989A (es) * 2015-08-19 2018-06-19 Vivus Inc Formulaciones farmaceuticas.
GB201600376D0 (en) 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
US10618547B2 (en) * 2017-09-26 2020-04-14 Steering Solutions Ip Holding Corporation Regenerative current limiting of DC machines
WO2020012498A1 (en) 2018-07-13 2020-01-16 Council Of Scientific & Industrial Research Solid dispersion comprising an anticancer compound with improved solubility and efficacy
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
WO2020117134A1 (en) 2018-12-04 2020-06-11 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Stable tacrolimus ointment formulation for topical treatment of skin conditions
GR1009790B (el) * 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物
US20220313611A1 (en) * 2021-03-12 2022-10-06 Board Of Regents, The University Of Texas System Methods to prepare dry powders using suspension based thin film freezing
CN114469847A (zh) * 2021-12-29 2022-05-13 北京鑫开元医药科技有限公司 他克莫司栓剂及其制备方法和用途
CN116159034B (zh) * 2023-04-23 2023-07-04 国药集团川抗制药有限公司 一种他克莫司缓释胶囊及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925231A (ja) 1983-07-11 1984-02-09 Hitachi Ltd シリコンウエ−ハ
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPH0650393B2 (ja) 1985-07-30 1994-06-29 日本合成ゴム株式会社 ポジ型放射線感応性組成物
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DK0669127T3 (da) * 1992-11-18 1999-12-06 Fujisawa Pharmaceutical Co Farmaceutisk præparat med forlænget virkning
JPH06227732A (ja) 1993-02-02 1994-08-16 Sharp Corp 複写機におけるシート後処理装置
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
TW426516B (en) 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
ATE464900T1 (de) * 1998-03-26 2010-05-15 Astellas Pharma Inc Retardpräparat mit makroliden wie tacrolimus
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) * 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
JP3405261B2 (ja) 1999-03-30 2003-05-12 トヨタ自動車株式会社 筒内噴射式火花点火内燃機関
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
AU2001250646A1 (en) * 2000-04-17 2001-10-30 Yamanouchi Pharmaceutical Co..Ltd. Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
EP1289560A1 (en) 2000-06-12 2003-03-12 SmithKline Beecham Corporation Novel solid dispersion compositions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
RU2330642C2 (ru) * 2001-07-06 2008-08-10 Лайфсайкл Фарма А/С Регулируемая агломерация
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
MXPA06000370A (es) * 2003-07-09 2006-03-28 Chong Kun Dang Pharm Corp Dispersion solida de tacrolimus.
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
SI1663217T1 (sl) * 2003-08-29 2010-10-29 Lifecycle Pharma As Trdne disperzije, ki vsebujejo takrolimus
US20070122482A1 (en) * 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
NO320286B1 (no) 2003-11-19 2005-11-21 Dag Herman Zeiner-Gundersen Turbin for kraftproduksjon
AU2005219443A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
EA200701998A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции для инъекций наночастиц иммунодепрессивных соединений
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
US8383135B2 (en) 2010-12-03 2013-02-26 Richard C. Fuisz Solid dosage form that promotes reliable oral, esophageal and GI transit
JP6227732B1 (ja) 2016-08-23 2017-11-08 株式会社コロプラ 仮想空間において入力を支援するための方法および装置、ならびに当該方法をコンピュータに実行させるプログラム

Also Published As

Publication number Publication date
WO2005020994A1 (en) 2005-03-10
AU2004267909B2 (en) 2008-12-18
JP2007504102A (ja) 2007-03-01
EP1663216A1 (en) 2006-06-07
PL1663217T3 (pl) 2010-12-31
US20110256190A1 (en) 2011-10-20
CA2537041C (en) 2012-04-03
US20110250277A1 (en) 2011-10-13
BRPI0414000A (pt) 2006-10-24
AU2004267909A1 (en) 2005-03-10
BRPI0414000B8 (pt) 2021-05-25
BRPI0414000B1 (pt) 2019-11-05
US20180228779A1 (en) 2018-08-16
US20110251232A1 (en) 2011-10-13
NO20061430L (no) 2006-05-29
CA2537044A1 (en) 2005-03-10
US20110251231A1 (en) 2011-10-13
US10548880B2 (en) 2020-02-04
BRPI0413927A (pt) 2006-10-24
US7994214B2 (en) 2011-08-09
EP1663216B1 (en) 2011-11-02
US8889186B2 (en) 2014-11-18
BRPI0413927B1 (pt) 2019-11-12
US20140066473A1 (en) 2014-03-06
US8486993B2 (en) 2013-07-16
JP2011251972A (ja) 2011-12-15
PL1663216T3 (pl) 2012-03-30
US20200289478A1 (en) 2020-09-17
EP1663217B1 (en) 2010-07-07
US20160166551A1 (en) 2016-06-16
BRPI0413927B8 (pt) 2021-05-25
JP4996249B2 (ja) 2012-08-08
US8586084B2 (en) 2013-11-19
CA2537044C (en) 2012-04-17
US8617599B2 (en) 2013-12-31
AU2004267910B2 (en) 2011-01-06
EP1663217A1 (en) 2006-06-07
ATE473003T1 (de) 2010-07-15
US20100008984A1 (en) 2010-01-14
US20110263632A1 (en) 2011-10-27
US20160243090A1 (en) 2016-08-25
US20130189318A1 (en) 2013-07-25
US20140073665A1 (en) 2014-03-13
US8889185B2 (en) 2014-11-18
US20140065225A1 (en) 2014-03-06
US9161907B2 (en) 2015-10-20
US11129815B2 (en) 2021-09-28
WO2005020993A1 (en) 2005-03-10
CA2537041A1 (en) 2005-03-10
NO334986B1 (no) 2014-08-18
US8623411B2 (en) 2014-01-07
NO337869B1 (no) 2016-07-04
AU2004267910A1 (en) 2005-03-10
US9757362B2 (en) 2017-09-12
NO20061429L (no) 2006-05-29
US11077096B2 (en) 2021-08-03
US9763920B2 (en) 2017-09-19
US8623410B2 (en) 2014-01-07
DE602004028023D1 (de) 2010-08-19
US20180214422A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
HK1096032A1 (en) Solid dispersions comprising tacrolimus
WO2006108075A3 (en) Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2006013369A3 (en) Compositions forming non-lamellar dispersions
WO2005101540A3 (en) Oled device with short reduction
CY1120831T1 (el) Μεθοδοι μειωσης της συσσωματωσης toy il-1ra
WO2007033316A3 (en) Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
WO2007118125A3 (en) Location based reminders
WO2007076132A3 (en) Compositions comprising oriented, immobilized macromolecules and methods for their preparation
WO2004071808A3 (en) Vehicle information displays
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
WO2005077365A3 (en) Novel uses for proton pump inhibitors
EP1663959A4 (en) NEW AMIDINE COMPOUNDS FOR THE TREATMENT OF MICROBIAL INFECTIONS
WO2004087043A3 (en) Stable ophthalmic formulation containing an antibiotic and a corticosteroid
WO2008054341A3 (en) Method of bioimaging using nanocrystals of fluorescent dyes
NO20081364L (no) Amorfe faste dispersjoner
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2007005941A3 (en) Liver targeted conjugates
WO2006131806A3 (en) Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
WO2006112818A3 (en) 3' modified oligonucleotides containing pseudoisocytosine nucleobase derivatives and applications thereof as primers or probes
WO2008142569A3 (en) Topical compositions containing magaldrate
WO2005041747A3 (en) Stealthy nano agents
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof